|
|
PIKA |
|
Vaxjo ID |
183 |
|
Vaccine Adjuvant Name |
PIKA |
|
Adjuvant VO ID |
VO_0005379
|
|
Description |
stabilized chemical analog of dsRNA that is TLR3 agonist that induces mixed Th1/2 reponse |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
China (Yisheng Bio) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
dsRNA |
|
Storage |
2-8C |
|
Function |
enhancing antigen presentation by antigen-presenting cells (APCs) and inducing production of pro-inflammatory cytokines |
| References |
(Luyao, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=55]
Wijaya et al., 2017: Wijaya L, Tham CYL, Chan YFZ, Wong AWL, Li LT, Wang LF, Bertoletti A, Low JG. An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers. Vaccine. 2017; 35(8); 1175-1183. [PubMed: 28118938].
Zhang et al., 2016: Zhang Y, Zhang S, Li W, Hu Y, Zhao J, Liu F, Lin H, Liu Y, Wang L, Xu S, Hu R, Shao H, Li L. A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies. Virology. 2016; 489; 165-172. [PubMed: 26765968].
|
|
